Double-Blind, Randomized, Dose Ranging Study of Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) in HIV+ Subjects
NCT00002018
·
clinicaltrials.gov ↗
NA
Phase
COMPLETED
Status
60
Enrollment
INDUSTRY
Sponsor class
Conditions
HIV Infections
Interventions
DRUG:
Interferon alfa-n3
Sponsor
Interferon Sciences